IDH2 inhibitor (Enasidenib or AG‐221) and IDH1 inhibitor (Ivosidenib or AG‐120) have been approved by the Food and Drug Administration in the United States for targeted therapy of AML.6, 7. This evidence concerns the gene IDH1 and acute myeloid leukemia.